InBriefs

ASCEND study to evaluate a higher dose of Ionis-discovered nusinersen in SMA patients who had less than optimal response to Evrysdi

Ionis launches ‘Ion-ARPA’ initiative with an eye toward revolutionizing drug discovery – again

Ionis expands distribution agreement with Sobi to include TEGSEDI® in North America

ION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers

New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS

Lancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH

Lancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function

Ionis Statement on COVID-19

Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference